公开(公告)号：US10314893B2

公开(公告)日：2019-06-11

申请号：US15030377

申请日：2016-04-18

申请人： The Trustees of the University of Pennsylvania ,  University of Florida Research Foundation, Inc.

发明人： Henry Daniell ,  Qiuhong Li ,  Mohan K. Raizada

IPC分类号： A61K38/48 ,  A61K9/19 ,  A61K9/00 ,  A61K38/22 ,  A61K9/16 ,  A61K9/50 ,  C12N9/48 ,  C12N15/82 ,  A61K38/16 ,  A61K36/23 ,  A61K36/28 ,  A61K36/31 ,  C07K14/28 ,  A61K47/65 ,  A61K47/64

摘要： Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

公开(公告)号：US20190077838A1

公开(公告)日：2019-03-14

申请号：US16197751

申请日：2018-11-21

申请人： INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY

发明人： Kyung A. CHO ,  Jae Sung LIM ,  Joon Haeng RHEE

IPC分类号： C07K14/315 ,  C07K14/28 ,  A61K38/16 ,  A61K39/02 ,  A61K39/09

摘要： The present invention relates to a method for inhibiting, improving, or preventing aging, comprising administering to a subject in need thereof a composition comprising a recombinant protein of flagellin, which is the constituent of Vibrio vulnificus flagella, fused with a pathogenic protein antigen, which is pneumococcal surface protein A (PsaA) of Streptococcus pneumonia. According to the present invention, the recombinant protein of the present invention can improve external and internal aging-related malfunctions and enhance immunity. Also, the composition of the present invention can easily perform immunization through mucosal administration.

公开(公告)号：US20180360944A1

公开(公告)日：2018-12-20

申请号：US16061853

申请日：2016-12-09

申请人： MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.

发明人： Tarun SHARMA ,  Neeraj JOSHI ,  Vibhu KANCHAN ,  Deepa SIKRIWAL ,  Nidhi SHUKLA ,  Davinder GILL

IPC分类号： A61K39/02 ,  C12P1/04 ,  C12P21/02 ,  C07K14/28

摘要： The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.

公开(公告)号：US10086037B2

公开(公告)日：2018-10-02

申请号：US13561225

申请日：2012-07-30

申请人： Tapas Das Gupta ,  Ananda Chakrabarty ,  Craig Beattie ,  Tohru Yamada

发明人： Tapas Das Gupta ,  Ananda Chakrabarty ,  Craig Beattie ,  Tohru Yamada

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K49/00 ,  A61K49/04 ,  A61K49/08 ,  A61K49/14 ,  C07K14/21 ,  C07K14/415 ,  A61M5/00 ,  C07K14/00 ,  C07K14/22 ,  C07K14/225 ,  C07K14/235 ,  C07K14/28 ,  C07K14/32 ,  C12Q1/02 ,  C12Q1/04 ,  A61K47/54 ,  A61K47/64 ,  B82Y5/00

摘要： The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.

公开(公告)号：US20180073031A1

公开(公告)日：2018-03-15

申请号：US15701498

申请日：2017-09-12

申请人： Massachusetts Institute of Technology

发明人： Christopher Voigt ,  Mao Taketani

IPC分类号： C12N15/74 ,  C07K14/28 ,  A61K49/00

CPC分类号： C12N15/74 ,  A61K38/00 ,  A61K49/0097 ,  C07K14/28 ,  C12N15/635 ,  C12Q1/6897

摘要： The present disclosure relates, in some aspects, to bile acid sensors.

公开(公告)号：US09902760B2

公开(公告)日：2018-02-27

申请号：US13813844

申请日：2012-11-21

申请人： Bioven 3 Limited

发明人： Keith Alan Charlton ,  Erik D'Hondt

IPC分类号： C07K14/485 ,  C07K14/475 ,  C07K14/48 ,  A61K39/00 ,  C07K14/28 ,  C07K14/47 ,  C07K14/50 ,  C07K14/71 ,  C07K14/495 ,  C07K14/65 ,  C12N9/12 ,  C12N9/64

CPC分类号： C07K14/485 ,  A61K39/0005 ,  A61K39/0011 ,  A61K2039/645 ,  A61K2039/70 ,  C07K14/28 ,  C07K14/4748 ,  C07K14/475 ,  C07K14/4753 ,  C07K14/48 ,  C07K14/495 ,  C07K14/50 ,  C07K14/65 ,  C07K14/71 ,  C07K2319/40 ,  C12N9/12 ,  C12N9/6424 ,  Y02P20/582

摘要： A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.

公开(公告)号：US20160289277A1

公开(公告)日：2016-10-06

申请号：US15037045

申请日：2014-11-17

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

发明人： Roland W. HERZOG ,  Henry DANIELL

IPC分类号： C07K14/28 ,  C12N15/82 ,  A61K38/45 ,  C07K14/755 ,  A61K38/37

CPC分类号： C07K14/28 ,  A61K36/00 ,  A61K38/36 ,  A61K38/37 ,  A61K38/45 ,  A61K38/47 ,  C07K14/755 ,  C07K2319/00 ,  C12N15/8214 ,  C12N15/8257 ,  C12Y204/00 ,  C12Y302/0102 ,  C12Y302/01022 ,  Y02A50/471

摘要： Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein. Finally, the method can effectively be used to reverse or reduce undesirable pre-existing inhibitor titers.

摘要翻译： 对于患有血友病或其他遗传性蛋白质缺乏症的患者，蛋白质替代疗法通常由致病性抗体反应复杂化，包括中和治疗性蛋白质的抗体或易于形成IgE的潜在的威胁生命的过敏反应的抗体。 使用鼠和犬血友病作为模型，我们已经制定了一种针对这种非侵入性反应的预防方案，不包括对患者细胞的免疫抑制或遗传操作。 在植物细胞中生物封装的叶绿体中表达的凝血因子的口服递送在蛋白质替代疗法中有效阻断了抑制性抗体的形成。 与对照相比，抑制剂滴度几乎不可检测，并且在治疗的受试者中高达100倍。 此外，该治疗消除了在静脉内凝血因子蛋白质暴露四至六次后发生的致命过敏反应。 最后，该方法可有效地用于逆转或减少不期望的预先存在的抑制剂滴度。

公开(公告)号：US20160031947A1

公开(公告)日：2016-02-04

申请号：US14887100

申请日：2015-10-19

申请人： The Board of Trustees of the University of Illinois

发明人： Ananda Chakrabarty ,  Tapas Das Gupta ,  Tohru Yamada ,  Arsenio Fialho

IPC分类号： C07K14/28 ,  C07K14/22 ,  C07K14/235 ,  A61K35/13 ,  A61K49/22 ,  A61K38/16 ,  A61K38/10 ,  A61K38/08 ,  A61K49/04 ,  A61K49/14 ,  C07K14/195 ,  A61K45/06

CPC分类号： C07K14/28 ,  A61K35/13 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/164 ,  A61K45/06 ,  A61K49/00 ,  A61K49/04 ,  A61K49/14 ,  A61K49/221 ,  C07K14/195 ,  C07K14/21 ,  C07K14/22 ,  C07K14/235 ,  C07K2319/02

摘要： The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.

公开(公告)号：US20160017007A1

公开(公告)日：2016-01-21

申请号：US14770919

申请日：2014-03-11

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Matthew WALDOR ,  Xiaohui ZHOU ,  Benjamin GEWURZ

IPC分类号： C07K14/28 ,  A61K35/74 ,  A61K39/02

CPC分类号： C07K14/28 ,  A61K35/74 ,  A61K39/02 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/31 ,  C07K2319/40 ,  C07K2319/50 ,  C07K2319/60

摘要： Embodiments described are immunosuppressant therapeutics and compositions comprising a Vop protein derived from Vibro parahaemolyticus; and drug delivery vehicles derived from a V. parahaemolyticus expressing a mutant VopZ protein lacking amino acid residue 38-62.

摘要翻译： 所描述的实施方案是免疫抑制剂治疗剂和包含源自副溶血弧菌的Vop蛋白的组合物; 来自副溶血性弧菌的药物递送载体，其表达缺少氨基酸残基38-62的突变型VopZ蛋白。

公开(公告)号：US09133247B2

公开(公告)日：2015-09-15

申请号：US12696712

申请日：2010-01-29

申请人： Samuel Bogoch ,  Elenore S. Bogoch

发明人： Samuel Bogoch ,  Elenore S. Bogoch

IPC分类号： C07H21/04 ,  C07K14/005 ,  C07K14/195 ,  C07K14/205 ,  C07K14/21 ,  C07K14/22 ,  C07K14/24 ,  C07K14/245 ,  C07K14/255 ,  C07K14/26 ,  C07K14/27 ,  C07K14/28 ,  C07K14/285 ,  C07K14/30 ,  C07K14/305 ,  C07K14/31 ,  C07K14/315 ,  C07K14/32 ,  C07K14/33 ,  C07K14/335 ,  C07K14/34 ,  C07K14/345 ,  C07K14/35 ,  C07K14/355 ,  C07K14/36 ,  C07K14/37 ,  C07K14/38 ,  C07K14/385 ,  C07K14/39 ,  C07K14/40 ,  C07K14/405 ,  C07K14/415 ,  C07K14/44 ,  C07K14/445 ,  C07K14/47 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/53 ,  C07K14/195 ,  C07K14/205 ,  C07K14/21 ,  C07K14/22 ,  C07K14/24 ,  C07K14/245 ,  C07K14/255 ,  C07K14/26 ,  C07K14/27 ,  C07K14/28 ,  C07K14/285 ,  C07K14/30 ,  C07K14/305 ,  C07K14/31 ,  C07K14/315 ,  C07K14/32 ,  C07K14/33 ,  C07K14/335 ,  C07K14/34 ,  C07K14/345 ,  C07K14/35 ,  C07K14/355 ,  C07K14/36 ,  C07K14/37 ,  C07K14/38 ,  C07K14/385 ,  C07K14/39 ,  C07K14/40 ,  C07K14/405 ,  C07K14/415 ,  C07K14/44 ,  C07K14/445 ,  C07K14/47 ,  C12N2710/24122 ,  C12N2760/16022 ,  C12N2760/16122 ,  Y02A50/412

摘要： Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.